Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthonie W A Lensing

Showing results (1-10 of 69) with videos related to

Pageof 7
Sort By:
Seminars in Thrombosis and Hemostasis|December 16, 2006
New strategies for the treatment of acute venous thromboembolismPaolo Prandoni, Anthonie W A Lensing, Raffaele Pesavento
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|April 3, 2009
Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patientsAlexander G G Turpie, Anthonie W A Lensing, Takeshi Fuji, et al.
Clinical Pharmacokinetics|September 8, 2011
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke preventionWolfgang Mueck, Anthonie W A Lensing, Giancarlo Agnelli, et al.
Thrombosis and Haemostasis|July 31, 2015
Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studiesHilde A M Kooistra, Martin Gebel, Kurtulus Sahin, et al.
Thrombosis and Haemostasis|September 28, 2002
The diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein thrombosisPaolo Prandoni, Anthonie W A Lensing, Enrico Bernardi, et al.
Current Medical Research and Opinion|April 9, 2015
Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis programHiroshi Matsuo, Martin Prins, Anthonie W A Lensing, et al.
Pediatric Neurology|January 15, 2022
Anticoagulant Treatment for Pediatric Infection-Related Cerebral Venous ThrombosisMayte Sánchez van Kammen, Christoph Male, Philip Connor, et al.
Current Medical Research and Opinion|January 18, 2014
Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolismBonno van Bellen, Luke Bamber, Francine Correa de Carvalho, et al.
Journal of Thrombosis and Haemostasis : JTH|March 7, 2022
Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolismIngrid M Bistervels, Roisin Bavalia, Martin Gebel, et al.
Thrombosis Research|December 9, 2014
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trialMartin H Prins, Luke Bamber, Stefan J Cano, et al.
Pageof 7

Showing results (1-10 of 69) with videos related to

Sort By:
Pageof 7
Seminars in Thrombosis and Hemostasis|December 16, 2006
New strategies for the treatment of acute venous thromboembolismPaolo Prandoni, Anthonie W A Lensing, Raffaele Pesavento
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|April 3, 2009
Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patientsAlexander G G Turpie, Anthonie W A Lensing, Takeshi Fuji, et al.
Clinical Pharmacokinetics|September 8, 2011
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke preventionWolfgang Mueck, Anthonie W A Lensing, Giancarlo Agnelli, et al.
Thrombosis and Haemostasis|July 31, 2015
Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studiesHilde A M Kooistra, Martin Gebel, Kurtulus Sahin, et al.
Thrombosis and Haemostasis|September 28, 2002
The diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein thrombosisPaolo Prandoni, Anthonie W A Lensing, Enrico Bernardi, et al.
Current Medical Research and Opinion|April 9, 2015
Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis programHiroshi Matsuo, Martin Prins, Anthonie W A Lensing, et al.
Pediatric Neurology|January 15, 2022
Anticoagulant Treatment for Pediatric Infection-Related Cerebral Venous ThrombosisMayte Sánchez van Kammen, Christoph Male, Philip Connor, et al.
Current Medical Research and Opinion|January 18, 2014
Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolismBonno van Bellen, Luke Bamber, Francine Correa de Carvalho, et al.
Journal of Thrombosis and Haemostasis : JTH|March 7, 2022
Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolismIngrid M Bistervels, Roisin Bavalia, Martin Gebel, et al.
Thrombosis Research|December 9, 2014
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trialMartin H Prins, Luke Bamber, Stefan J Cano, et al.
Pageof 7